4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, Frank G. Haluska, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P Hughes, Neil P. Shah, Hagop M. Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Charité - Universitätsmedizin Berlin, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Hôpital Lyon Sud, Imperial College London, Winship Cancer Institute, University of Michigan, U-M Rogel Cancer Center, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, ARIAD Pharmaceuticals (United States), Inserm, Centre Hospitalier Universitaire de Poitiers, University of Utah, Huntsman Cancer Institute, Jena University Hospital, South Australia Pathology, University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2763319969